Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H5N1 - Seqirus

Drug Profile

Influenza A virus vaccine H5N1 - Seqirus

Alternative Names: Aflunov; aH5N1c; AUDENZ; FCC H5N1; Flu Cell Culture H5N1; Influenza A (H5N1) Monovalent Vaccine, Adjuvanted - Seqirus; Influenza A virus strain H5N1 vaccine - Seqirus; MF59®-Adjuvanted Pandemic Influenza Vaccine - Seqirus; MF59®-adjuvanted-H5N1 subunit vaccine; Pre-pandemic H5N1 influenza vaccine - Seqirus; Pre-pandemic influenza vaccine - Seqirus

Latest Information Update: 06 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Novartis Vaccines
  • Developer Seqirus
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 02 Jan 2023 Influenza A virus vaccine H5N1 is still in phase II trials for Influenza A virus H5N1 subtype (In children's, In infants, Prevention) in Estonia and Philippines (IM) (NCT04669691)
  • 15 Apr 2022 Seqirus completes a phase I trial in Influenza A virus H5N1 subtype (In children, In infants, Prevention) in Estonia and Philippines (IM) (NCT04669691)
  • 25 Feb 2022 Seqirus renews a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply Influenza A virus vaccine H5N1 in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top